Effect of Socioeconomic Status on Patients Supported with Contemporary Left Ventricular Assist Devices.


Journal

ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 14 6 2019
medline: 20 11 2020
entrez: 14 6 2019
Statut: ppublish

Résumé

Continuous-flow left ventricular assist devices (CF-LVADs) are increasingly used in advanced heart failure patients. Recent studies suggest that low socioeconomic status (SES) predicts worst survival after heart transplantation. Both individual-level and neighborhood-level SES (nSES) have been linked to cardiovascular health; however, the impact of SES in CF-LVAD patients remains unknown. We hypothesized that SES is a major determinant of CF-LVAD candidacy and postimplantation outcomes. A retrospective chart review was conducted on 362 patients between February 2009 and May 2016. Neighborhood-level SES was measured using the American Community Survey data and the Agency for Healthcare Research and Quality SES index score. Individual-level SES was self reported. Kaplan-Meier survival analysis and multivariable Cox proportional hazards regression determined survival statistics. Patients in the highest SES tertile were older (58 ± 13 vs. 53 ± 14; p < 0.001), less likely to be black or Hispanic (26% vs. 70%; p < 0.001), more likely to be married (87% vs. 65%; p < 0.001), more likely to have private insurance (50% vs. 39%; p < 0.001), and more likely to have employment (29% vs. 15%; p < 0.001) compared with patients in the lowest tertile. Low nSES was associated with a decreased risk of death (hazard ratio [HR], 0.580; 95% confidence interval [CI], 0.347-0.970; p = 0.038) in comparison to the high nSES. However, after adjusting for baseline clinical morbidities, the relationship was no longer present. When selecting patients for a LVAD, SES should not be thought of as an immutable risk factor. Carefully selected low-SES patients could be safely implanted with CF-LVAD with outcomes comparable to high-SES patients.

Identifiants

pubmed: 31192839
doi: 10.1097/MAT.0000000000001009
pii: 00002480-202004000-00008
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

373-380

Références

Miller LW, Guglin M. Patient selection for ventricular assist devices: A moving target. J Am Coll Cardiol 2013.61: 1209–1221.
Tsiouris A, Paone G, Nemeh HW, Brewer RJ, Morgan JA. Factors determining post-operative readmissions after left ventricular assist device implantation. J Heart Lung Transplant 2014.33: 1041–1047.
Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. food and drug administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: A prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011.57: 1890–1898.
Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. J Heart Lung Transplant 2017.36: 1080–1086.
Trivedi JR, Cheng A, Singh R, Williams ML, Slaughter MS. Survival on the heart transplant waiting list: Impact of continuous flow left ventricular assist device as bridge to transplant. Ann Thorac Surg 2014.98: 830–834.
Grady KL, Meyer PM, Dressler D, et al. Change in quality of life from after left ventricular assist device implantation to after heart transplantation. J Heart Lung Transplant 2003.22: 1254–1267.
Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure. JACC Heart Failure 2017.5: 110–119.
Akhter SA, Badami A, Murray M, et al. Hospital readmissions after continuous-flow left ventricular assist device implantation: Incidence, causes, and cost analysis. Ann Thorac Surg 2015.100: 884–889.
Forest SJ, Bello R, Friedmann P, et al. Readmissions after ventricular assist device: Etiologies, patterns, and days out of hospital. Ann Thorac Surg 2013.95: 1276–1281.
Maniar HS, Bell JM, Moon MR, et al. Prospective evaluation of patients readmitted after cardiac surgery: Analysis of outcomes and identification of risk factors. J Thorac Cardiovasc Surg 2014.147: 1013–1018.
Hawkins NM, Jhund PS, McMurray JJ, Capewell S. Heart failure and socioeconomic status: Accumulating evidence of inequality. Eur J Heart Fail 2012.14: 138–146.
Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: The multi-ethnic study of atherosclerosis. Arch Intern Med 2008.168: 2138–2145.
Bikdeli B, Wayda B, Bao H, et al. Place of residence and outcomes of patients with heart failure: Analysis from the telemonitoring to improve heart failure outcomes trial. Circ Cardiovasc Qual Outcomes 2014.7: 749–756.
Phelan JC, Link BG, Tehranifar P. Social conditions as fundamental causes of health inequalities: Theory, evidence, and policy implications. J Health Soc Behav 2010.51(suppl): S28–S40.
Díaz-Toro F, Verdejo HE, Castro PF. Socioeconomic inequalities in heart failure. Heart Fail Clin 2015.11: 507–513.
Kato N, Jaarsma T, Ben Gal T. Learning self-care after left ventricular assist device implantation. Curr Heart Fail Rep 2014.11: 290–298.
Emani S, Tumin D, Foraker RE, Hayes D Jr, Smith SA. Impact of insurance status on heart transplant wait-list mortality for patients with left ventricular assist devices. Clin Transplant 2017.31: 1399–0012.
Smith SA, Hasan AK, Binkley PF, Foraker RE. The impact of insurance and socioeconomic status on outcomes for patients with left ventricular assist devices. J Surg Res 2014.191: 302–308.
Clerkin KJ, Garan AR, Wayda B, et al. Impact of socioeconomic status on patients supported with a left ventricular assist device. Circ Heart Fail 2016.9: e003215.
Verma AK, Schulte PJ, Bittner V, et al. socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes. Am Heart J 2017.183: 54–61.
Snipelisky D, Stulak JM, Schettle SD, Sharma S, Kushwaha SS, Dunlay SM. Psychosocial characteristics and outcomes in patients with left ventricular assist device implanted as destination therapy. Am Heart J 2015.170: 887–894.
Cowger J, Sundareswaran K, Rogers JG, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: The HeartMate II risk score. J Am Coll Cardiol 2013.61: 313–321.
Stewart GC, Kittleson MM, Patel PC, Cowger JA. INTERMACS (interagency registry for mechanically assisted circulatory support) profiling identifies ambulatory patients at high risk on medical therapy after hospitalizations for heart failure CLINICAL PERSPECTIVE. Circ Heart Fail 2016.9: e003032.
Topkara VK, Garan AR, Ton V, Yuzefpolskaya M. Red cell distribution width (RDW) predicts 90-day mortality in continuous-flow left ventricular assist device (CF-LVAD) patients. J Heart Lung Transplant 2016.35: S110.
Havranek EP, Mujahid MS, Barr DA, et al.; American Heart Association Council on Quality of Care and Outcomes Research, Council on Epidemiology and Prevention, Council on Cardiovascular and Stroke Nursing, Council on Lifestyle and Cardiometabolic Health, and Stroke Council: Social determinants of risk and outcomes for cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2015.132: 873–898.
Devore AD, Mentz RJ, Patel CB. Medical management of patients with continuous-flow left ventricular assist devices. Curr Treat Options Cardiovasc Med 2014.16: 283.

Auteurs

Autumn M Clemons (AM)

From the Division of Cardiology, Department of Medicine.

Raul J Flores (RJ)

From the Division of Cardiology, Department of Medicine.

Raia Blum (R)

From the Division of Cardiology, Department of Medicine.

Brian Wayda (B)

From the Division of Cardiology, Department of Medicine.

Danielle L Brunjes (DL)

From the Division of Cardiology, Department of Medicine.

Marlena Habal (M)

From the Division of Cardiology, Department of Medicine.

Raymond C Givens (RC)

From the Division of Cardiology, Department of Medicine.

Lauren K Truby (LK)

From the Division of Cardiology, Department of Medicine.

A Reshad Garan (AR)

From the Division of Cardiology, Department of Medicine.

Melana Yuzefpolskaya (M)

From the Division of Cardiology, Department of Medicine.

Koji Takeda (K)

Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center - New York Presbyterian, New York, New York.

Hiroo Takayama (H)

Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center - New York Presbyterian, New York, New York.

Maryjane A Farr (MA)

From the Division of Cardiology, Department of Medicine.

Yoshifumi Naka (Y)

Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center - New York Presbyterian, New York, New York.

Paolo C Colombo (PC)

From the Division of Cardiology, Department of Medicine.

Veli K Topkara (VK)

From the Division of Cardiology, Department of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH